GABRD | Gamma-aminobutyric acid (GABA) A receptor, delta | Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GABRG1 | Gamma-aminobutyric acid (GABA) A receptor, gamma 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GABRG2 | Gamma-aminobutyric acid (GABA) A receptor, gamma 2 | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GAD1 | Glutamate decarboxylase 1 (brain, 67kDa) | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enriched |
GAD2 | Glutamate decarboxylase 2 (pancreatic islets and brain, 65kDa) | Enzymes
| | | | | Tissue enriched |
GAP43 | Growth associated protein 43 | Plasma proteins Transporters
| | | | | Tissue enriched |
GDAP1L1 | Ganglioside induced differentiation associated protein 1-like 1 | Predicted membrane proteins
| | | | | Tissue enriched |
GFAP | Glial fibrillary acidic protein | Candidate cardiovascular disease genes Disease related genes Plasma proteins
| | | | | Tissue enriched |
GLRA3 | Glycine receptor, alpha 3 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GNAO1 | Guanine nucleotide binding protein (G protein), alpha activating activity polypeptide O | Disease related genes
| | | | | Tissue enriched |
GNG3 | Guanine nucleotide binding protein (G protein), gamma 3 | RAS pathway related proteins
| | | | | Tissue enriched |
GPM6A | Glycoprotein M6A | Predicted membrane proteins
| | | | | Tissue enriched |
GPM6B | Glycoprotein M6B | Predicted membrane proteins
| | | | | Tissue enriched |
GPR137C | G protein-coupled receptor 137C | Predicted membrane proteins
| | | | | Tissue enriched |
GPR158 | G protein-coupled receptor 158 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPR17 | G protein-coupled receptor 17 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPR26 | G protein-coupled receptor 26 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPR37L1 | G protein-coupled receptor 37 like 1 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPR62 | G protein-coupled receptor 62 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPR75 | G protein-coupled receptor 75 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GRIA1 | Glutamate receptor, ionotropic, AMPA 1 | FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
GRIA2 | Glutamate receptor, ionotropic, AMPA 2 | Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
GRIA4 | Glutamate receptor, ionotropic, AMPA 4 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GRIK3 | Glutamate receptor, ionotropic, kainate 3 | Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
GRIN1 | Glutamate receptor, ionotropic, N-methyl D-aspartate 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins Transporters
| | | | | Tissue enriched |
GRIN2B | Glutamate receptor, ionotropic, N-methyl D-aspartate 2B | Disease related genes FDA approved drug targets Predicted membrane proteins RAS pathway related proteins
| | | | | Tissue enriched |
GRIN3A | Glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enriched |
GRM3 | Glutamate receptor, metabotropic 3 | G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
GRM5 | Glutamate receptor, metabotropic 5 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
HAPLN2 | Hyaluronan and proteoglycan link protein 2 | Predicted secreted proteins
| | | | | Tissue enriched |
HPCA | Hippocalcin | Plasma proteins
| | | | | Tissue enriched |
HPCAL4 | Hippocalcin like 4 | | | | | | Tissue enriched |
HRH3 | Histamine receptor H3 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
HS3ST2 | Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 | Enzymes
| | | | | Tissue enriched |
HS3ST4 | Heparan sulfate (glucosamine) 3-O-sulfotransferase 4 | Enzymes Predicted membrane proteins
| | | | | Tissue enriched |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
HTR2C | 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
HTR5A-AS1 | HTR5A antisense RNA 1 | | | | | | Tissue enriched |
IL1RAPL1 | Interleukin 1 receptor accessory protein-like 1 | Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
JPH3 | Junctophilin 3 | Disease related genes Predicted membrane proteins
| | | | | Tissue enriched |
KCNA1 | Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | Disease related genes FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNA6 | Potassium voltage-gated channel, shaker-related subfamily, member 6 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC1 | Potassium voltage-gated channel, Shaw-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNC2 | Potassium voltage-gated channel, Shaw-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNF1 | Potassium voltage-gated channel, subfamily F, member 1 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ9 | Potassium inwardly-rectifying channel, subfamily J, member 9 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNK12 | Potassium channel, subfamily K, member 12 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNN1 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNQ3 | Potassium voltage-gated channel, KQT-like subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |